Aldeyra Prepares to Submit Dry Eye Disease Treatment Reproxalap to FDA

Lexington, Mass.-based Aldeyra Therapeutics reported that its reproxalap hit the mark in the Phase III Tranquility-2 study for dry eye disease. The drug showed statistical superiority for its two primary endpoints.